Compare
SANUWAVE Health, Inc. vs TriSalus Life Sciences, Inc. vs SS Innovations International, Inc. vs KORU Medical Systems, Inc.
| Latest fiscal year | SANUWAVE Health, Inc. SNWV | TriSalus Life Sciences, Inc. TLSI | SS Innovations International, Inc. SSII | KORU Medical Systems, Inc. KRMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $44.05M | $45.15M | $42.48M | $41.13M |
| Revenue growth (YoY) | +35.0% | +53.4% | +105.7% | +22.2% |
| Gross margin | 77.1% (computed) | 84.6% | 46.0% | 62.3% |
| Operating margin | 11.2% | -59.7% | -19.3% | -7.2% |
| Net margin | 26.8% | -86.9% | -28.5% | -6.4% |
| Net income | $11.81M | -$39.23M | -$12.13M | -$2.64M |
| EPS (Diluted) | $0.41 | -$1.84 | -$0.06 | -$0.06 |
| Operating cash flow | $3.88M | -$18.01M | -$18.54M | $462.4K |
| Free cash flow | $1.93M | -$18.93M | -$22.20M | -$470.1K |
| Cash & equivalents | $11.96M | $20.44M | $3.21M | $8.87M |
| Total assets | $37.34M | $35.33M | $74.23M | $28.20M |
| Total liabilities | $35.72M | $69.19M | $36.01M | $11.15M |
| Shareholders' equity | $1.62M | -$33.86M | $38.22M | $17.05M |
| Return on year-end equity | 729.6% | n/a | -31.7% | -15.5% |
| Shares outstanding | 8.59M | 50.00M | 194.17M | 46.37M |
Revenue, most recent five fiscal years
| Fiscal year | SANUWAVE Health, Inc. | TriSalus Life Sciences, Inc. | SS Innovations International, Inc. | KORU Medical Systems, Inc. |
|---|---|---|---|---|
| Latest | $44.05M Ended 2025-12-31 | $45.15M Ended 2025-12-31 | $42.48M Ended 2025-12-31 | $41.13M Ended 2025-12-31 |
| 1 year earlier | $32.63M Ended 2024-12-31 | $29.43M Ended 2024-12-31 | $20.65M Ended 2024-12-31 | $33.65M Ended 2024-12-31 |
| 2 years earlier | $20.40M Ended 2023-12-31 | $18.51M Ended 2023-12-31 | $5.88M Ended 2023-12-31 | $28.52M Ended 2023-12-31 |
| 3 years earlier | $16.74M Ended 2022-12-31 | $12.40M Ended 2022-12-31 | $1.44M Ended 2022-12-31 | $27.90M Ended 2022-12-31 |
| 4 years earlier | $13.01M Ended 2021-12-31 | n/a | n/a | $23.49M Ended 2021-12-31 |